The MHRA has warned of reports of interstitial lung disease and pneumonitis, including severe cases, with CDK4/6 inhibitors (abemaciclib▼, palbociclib▼, ribociclib▼)

OnMedica

Jun 17, 2021

Trastuzumab deruxtecan recommended within CDF for breast cancer

Regulatory alerts NICE guidelines

Regulatory Alerts, Oncology, Breast cancer, Oncology Room

Trastuzumab deruxtecan recommended within CDF for breast cancer

OnMedica

May 26, 2021

New guidance for fast-track breast cancer radiotherapy treatment published

Regulatory alerts

Regulatory Alerts, Cancer, Breast cancer, Oncology Room

New guidance for fast-track breast cancer radiotherapy treatment published

OnMedica

May 13, 2021

#VisualAbstract: Sacituzumab govitecan increased survival in metastatic triple-negative breast cancer

Quality Evidence Briefings Visual Abstracts

Quality Evidence Briefings, Cancer, Oncology, Breast cancer, Oncology Room

#VisualAbstract: Sacituzumab govitecan increased survival in metastatic triple-negative breast cancer

2 Minute Medicine

May 05, 2021

Trastuzumab deruxtecan recommended in NICE draft guidance for use in the CDF for breast cancer after two or more anti-HER2 therapies

Regulatory alerts NICE guidelines

Regulatory Alerts, Breast cancer, Oncology Room

Trastuzumab deruxtecan recommended in NICE draft guidance for use in the CDF for breast cancer after two or more anti-HER2 therapies

OnMedica

Apr 20, 2021

Clinicopathological heterogeneity in triple-negative breast cancers associated with variable prognosis and therapeutic outcomes

Quality Evidence Briefings

Quality Evidence Briefings, Cancer, Oncology, Breast cancer, Oncology Room

Clinicopathological heterogeneity in triple-negative breast cancers associated with variable prognosis and therapeutic outcomes

2 Minute Medicine

Apr 12, 2021

Patients set to benefit from five-minute breast cancer treatment

Regulatory alerts

Regulatory Alerts, Oncology, Breast cancer, Oncology Room

Patients set to benefit from five-minute breast cancer treatment

OnMedica

Apr 04, 2021

Quality Evidence Briefings Visual Abstracts

Oncology, Breast cancer, Oncology Room

#VisualAbstract: Early discontinuation of endocrine therapy may increase risk of breast cancer recurrence in premenopausal women

2 Minute Medicine

Mar 24, 2021

#VisualAbstract: Salpingo-oophorectomy may reduce short-term risk of breast cancer in women with BRCA1 and BRCA2 variants

Quality Evidence Briefings Visual Abstracts

Quality Evidence Briefings, Cancer, Oncology, Breast cancer, Oncology Room

#VisualAbstract: Salpingo-oophorectomy may reduce short-term risk of breast cancer in women with BRCA1 and BRCA2 variants

2 Minute Medicine

Mar 17, 2021

#VisualAbstract: Pyrotinib plus capecitabine improves progression-free survival in HER2⁺ metastatic breast cancer

Quality Evidence Briefings Visual Abstracts

Quality Evidence Briefings, Cancer, Oncology, Breast cancer, Oncology Room

#VisualAbstract: Pyrotinib plus capecitabine improves progression-free survival in HER2⁺ metastatic breast cancer

2 Minute Medicine

Mar 10, 2021

#VisualAbstract: Aromatase inhibitors superior to tamoxifen for progression-free survival in HR⁺ advanced breast cancer

Quality Evidence Briefings Visual Abstracts

Quality Evidence Briefings, Cancer, Oncology, Breast cancer, Oncology Room

#VisualAbstract: Aromatase inhibitors superior to tamoxifen for progression-free survival in HR⁺ advanced breast cancer

2 Minute Medicine

Mar 04, 2021

Ribociclib with fulvestrant now recommended for routine use for the treatment of breast cancer

Regulatory alerts

Regulatory Alerts, Cancer, Oncology, Breast cancer, Oncology Room

Ribociclib with fulvestrant now recommended for routine use for the treatment of breast cancer

OnMedica

Feb 26, 2021

Quality Evidence Briefings Visual Abstracts

Quality Evidence Briefings, Oncology, Breast cancer, Oncology Room

#VisualAbstract: CARG-BC score may predict risk of severe chemotherapy toxicity in elderly patients with early breast cancer

2 Minute Medicine

Feb 24, 2021